BiotechTube

Tabalumab Auto-Injector + Tabalumab Prefilled Syringe

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Erythematosus, Systemic

Conditions

Lupus Erythematosus, Systemic

Trial Timeline

Jan 1, 2014 → Nov 1, 2015

NCT ID
NCT02041091

About Tabalumab Auto-Injector + Tabalumab Prefilled Syringe

Tabalumab Auto-Injector + Tabalumab Prefilled Syringe is a phase 3 stage product being developed by Eli Lilly for Lupus Erythematosus, Systemic. The current trial status is terminated. This product is registered under clinical trial identifier NCT02041091. Target conditions include Lupus Erythematosus, Systemic.

What happened to similar drugs?

8 of 20 similar drugs in Lupus Erythematosus, Systemic were approved

Approved (8) Terminated (6) Active (8)
✅tacrolimusAstellas PharmaApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved
✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved
✅Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Standard therapyGSK plcApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02041091Phase 3Terminated
NCT01676701Phase 3Terminated

Competing Products

20 competing products in Lupus Erythematosus, Systemic

See all competitors
ProductCompanyStageHype Score
Baricitinib + PlaceboEli LillyPhase 2
35
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
tacrolimusAstellas PharmaPhase 3
40
TacrolimusAstellas PharmaPre-clinical
26
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
32
tacrolimusAstellas PharmaApproved
35
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
40
E6742EisaiPhase 1/2
32
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 1
29
LY3471851 + PlaceboEli LillyPhase 2
35
Itolizumab [Bmab 600]BioconPhase 1
29